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Delay Discounting and Cannabinoid Enzyme Inhibitors 
 
 
Devin Andrew Galdieri 
 
Delay discounting is a measure of impulsive choice that is correlated with maladaptive behavior 
and psychological disorders. Disruptions to serotonin and dopamine pathways can cause changes 
in delay discounting, as can lesions to the prefrontal cortex and nucleus accumbens. The 
endocannabinoid system modulates other neurotransmitter systems, including dopamine and 
serotonin pathways. Cannabinoid receptors type 1 are found in relatively high concentrations in 
the nucleus accumbens and the prefrontal cortex. These receptors are activated by endogenous 
cannabinoids, which are synthesized on demand and broken down by catabolic enzymes. The 
action of these enzymes can be inhibited by a class of drugs known as cannabinoid enzyme 
inhibitors, which ultimately produce higher levels of endogenous cannabinoids by preventing 
their catabolic degradation. The present study examined effects of two cannabinoid enzyme 
inhibitors, URB597 and JZL195, on delay discounting in rats. Delay discounting was measured 
at baseline and after drug administration. Area under the curve and indifference points were not 
affected by any dose of either drug, but 7.5 mg/kg of JZL195 decreased percent larger-reinforcer 
choice at the lowest delay value and increased it at the highest delay value. URB597 increase 
percent larger-reinforcer choice only at one intermediate delay value. JZL195 increased response 
latencies at the 7.5 mg/kg dose. No systematic, dose-dependent effect of either drug on measures 
of delay discounting was observed. 
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1 
Delay Discounting and Cannabinoid Enzyme Inhibitors 
Delay discounting, a measure of impulsivity, has been implicated in a number of 
disorders and maladaptive behaviors including pathological gambling, substance abuse, 
attention-deficit/hyperactivity disorder (ADHD), schizophrenia, personality disorders, 
suicidality, and psychopathology in general (Castellanos-Ryan et al., 2016; Dom, De Wilde, 
Hulstijn, Brink, & Sabbe, 2006; Heerey, Robinson, McMahon, & Gold 2007; Kirby, Petry, & 
Bickel, 1999; Rogers, Moeller, Swann, & Clark, 2010; Wiehler & Peters, 2015; Wilson, 
Mitchell, Musser, Schmitt, & Nigg, 2011). One facet of impulsivity is impulsive choice, which 
can be defined as the choice of a smaller, more immediate reinforcer over a larger, delayed 
reinforcer (Ainslie, 1974, 1975). Conversely, self-control has been defined as the choice of a 
larger delayed reinforcer over a relatively smaller immediate reinforcer (Rachlin & Green, 1972).  
The purpose of the present experiment was to assess effects of drugs that alter the 
endocannabinoid system using a procedure designed to measure impulsive choice. Delay-
discounting procedures are commonly used to assess impulsive choice and there is experimental 
evidence that implicates serotonin (5-HT) and dopamine (DA), as well as the prefrontal cortex 
(PFC) and nucleus accumbens (NAc) in increased delay discounting (impulsive choice) (e.g., 
Bizot, Le Bihan, Puech, Hamon, & Thiébot, 1999; Cardinal, 2006; Evenden & Ryan, 1996; 
Winstanley, Theobald, Cardinal, & Robbins, 2004). The endocannabinoid system is an attractive 
target for research in general due to its therapeutic potential, and in terms of delay-discounting 
research, due to its effects on the neurotransmitter systems for 5-HT and DA and brain regions in 
the PFC and NAc (e.g., Lòpez-Moreno, González-Cuevas, Moreno, & Navarro, 2008; Reggio 
2009). There are two main receptor types in the endocannabinoid system and two main 
endogenous compounds that activate them (Reggio, 2009). The different physiological and 
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behavioral effects that follow activation of these different receptors and the neurotransmitters 
and brain regions affected by them provided rationale for choosing the drugs used in this study 
and those drugs’ likelihood of producing effects on delay discounting. Prior operant research on 
the endocannabinoid system is sparse and results are mixed, but the established therapeutic 
potential and long list of unanswered research questions suggest that there is still much to learn, 
particularly in matters of impulsivity and choice. 
Delay-Discounting Procedures  
Impulsive choice can be assessed several different ways. Delay discounting refers to a 
decrease in perceived value of a reinforcer as a function of the delay to that reinforcer. In this 
case, the impulsive choice would be selecting the smaller, more immediate reinforcer over the 
larger, delayed reinforcer. While impulsivity has been studied using different constructs and 
procedures (e.g., probability discounting, response inhibition), delay discounting is represented 
in a broad and robust body of behavior-analytic and pharmacological research.  
Impulsive choice has been measured with delay-discounting procedures across species 
for several decades (Vanderveldt, Oliveira, & Green, 2016), with many studies investigating 
pharmacological manipulations (e.g., Cardinal, Robins, & Everitt, 2000; Evenden & Ryan, 1999; 
Winstanley et al., 2004) and brain lesions (e.g., Cardinal, Pennicott, Sugathapala, Robbins, & 
Everritt, 2001; Mobini, Chiang, Ho, Bradshaw, & Szabadi, 2000; Mobini et al., 2002). A 
common delay-discounting procedure involves two choices presented simultaneously in discrete 
trials: one choice is associated with a larger, delayed reinforcer and one is associated with a 
smaller, more immediate reinforcer (e.g., Anderson & Woolverton, 2005; Evenden & Ryan, 
1999). The value of the larger reinforcer is said to be discounted as a function of delay, which is 
reflected in a shift in choice from the larger to the smaller reinforcer (i.e., from self-controlled 
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choice to impulsive choice) as the delay value increases. Responding in a delay-discounting 
procedure can typically be fitted to a hyperbolic curve, and several parameters of this curve can 
serve as quantitative measures of delay discounting (Mitchell, Wilson, & Karalunas, 2015). The 
area under the curve (AUC) of the delay-discounting function and the interpolated delay values 
at which the percent choice for the smaller and larger reinforcer are equal (indifference points) 
are two such measures (Myerson, Green, & Warusawitharana, 2001; Odum, 2011). Individuals 
who display many of the maladaptive behaviors mentioned above often have steeper delay-
discounting functions, lower AUC, and shorter indifference points, i.e., more impulsive choice, 
than the general population (e.g., Alessi & Petry, 2003; Amlung, Vedelago, Acker, & Balodis, 
Mackillop, 2016; Bickel, Odum, & Madden, 1999; Moody, Franck, & Bickel, 2016). Delay-
discounting procedures (described further in the Method section) have been effective at detecting 
effects of numerous drugs, including methylphenidate, amphetamine, nicotine, caffeine, and 
diazepam (Anderson & Diller, 2010; Diller, Saunders, & Anderson, 2008; Huskinson & 
Anderson, 2012; Krebs, Reilly, & Anderson, 2016; Slezak, & Anderson, 2011). Based on the 
ability of this procedure to detect impulsivity-altering effects of numerous drugs, and the relation 
between delay discounting and maladaptive behaviors related to impulse control, delay-
discounting procedure may serve as a useful tool to expand understanding of how the 
endocannabinoid system affects socially important behavior. 
Delay Discounting and Monoamines  
Agonists (compounds that increase the physiological action associated with a given 
receptor) that act on a variety of neurotransmitter systems have been studied for their effects on 
delay discounting. In particular, 5-HT and DA have been identified as major contributors to 
delay discounting, and many of the drugs that affect delay discounting directly affect 5-HT and 
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DA pathways (see Cardinal, 2006 for a review). Researchers investigating effects of stimulants 
such as d-amphetamine and methylphenidate (e.g., Cardinal, Robbins, & Everitt, 2000; Perry, 
Stairs, & Bardo, 2008) and 5-HT agonists such as fluoxetine and ketanserin (Carlisi et al., 2016; 
Darna et al., 2015) have demonstrated that, in some cases, drugs that increase DA and 5-HT 
activity can alter delay discounting. Although effects are often baseline-dependent, DA and 5-HT 
agonists tend to decrease delay discounting. Furthermore, lesions to 5-HT and DA systems in 
various brain regions, including the NAc and PFC, can affect delay discounting; however, the 
type of delay-discounting task, method of lesion, and the exact location of the lesion determined 
the directionality of effects on delay discounting (e.g., Basar et al., 2010; Bizot et al., 1999; 
Mobini, et al., 2000; Moschak & Mitchell, 2014; Simmons, Minamimoto, Murray, & Richmond, 
2010). Although many neurotransmitters and brain regions are likely involved in delay 
discounting, an abundance of evidence suggests 5-HT and DA are strong contributors and that 
the NAc and PFC are involved as well. 
Interestingly, the endocannabinoid system nodulates activity of both DA and 5-HT in the 
NAc and PFC and an abundance of cannabinoid receptors are present in these brain regions 
(Herkenham et al., 1990; Lòpez-Moreno et al., 2008). Given the endocannabinoid system’s 
involvement in neurotransmitter systems already known to affect delay discounting and its high 
receptor density in brain regions associated with delay discounting, it is not surprising that drugs 
that affect the endocannabinoid system can affect delay discounting (see Moreira, Jupp, Belin, & 
Dalley, 2015 for a review). Still, relatively little is known about the endocannabinoid system and 
its role in delay discounting. 
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The Endocannabinoid System 
The endocannabinoid system modulates activity of other neurotransmitters following 
activation of its own receptors (Reggio, 2009). The cannabinoid receptors include cannabinoid 
receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2), although several other receptor 
types without known endogenous ligands have been implicated as potential cannabinoid receptor 
types based on the affinity of various endogenous and exogenous cannabinoids for those 
receptors (Brown, 2007; Reggio, 2009). While CB1 receptors are found primarily on neuronal 
cells and in the brain, CB2 receptors are found predominantly on immune cells and peripheral 
tissue (Pertwee, 2004). There are three types of compounds that act directly on these receptors. 
Phytocannabinoids are the cannabinoids found in the plant Cannabis sativa and thus used in the 
recreational drug marijuana. Synthetic cannabinoids are man-made cannabinoids that often 
mimic naturally occurring cannabinoids and are developed and used in research settings. 
Although now widely illegal, synthetic cannabinoid agonists have been marketed for recreational 
use under such vague descriptions as “synthetic marijuana,” “herbal blends,” or “Spice” (Kemp 
et al., 2016). Endogenous cannabinoids (endocannabinoids) are those that are produced naturally 
in the bodies of animals (Lòpez-Moreno et al., 2008; Reggio, 2009). In addition to these natural 
and synthetic cannabinoid agonists, there are also compounds that indirectly increase activity at 
the cannabinoid receptors, such as cannabinoid enzyme inhibitors. Cannabinoid enzyme 
inhibitors reduce the ability of the enzymes that are responsible for catabolic degradation of the 
two known endocannabinoids (although other endocannabinoids may exist): 
arachidonoylglycerol (2-AG) and anandamide (AEA). Monoacylglycerol lipase (MAGL) is the 
enzyme that is responsible for the majority of 2-AG metabolism; fatty acid amide hydrolase 
(FAAH) is the enzyme that is responsible for the majority of AEA metabolism, as well as a small 
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amount of metabolism of 2-AG and some other non-cannabinoid compounds (Ahn, McKinney, 
& Cravatt, 2008). Pharmacological inhibition of these enzymes results in increased levels of 
endogenous cannabinoids, and thus, increased activity at the cannabinoid receptors (Ahn, et al., 
2008).  
Because CB1 is the cannabinoid receptor found primarily on neuronal cells, and because 
of the high density of CB1 receptors in areas such as the NAc and PFC, it is not surprising that a 
majority of behavioral research on cannabinoids and impulsivity implicate CB1 (Moreira et al., 
2015). CB1 receptors are activated by both AEA and 2-AG, although there are differences in 
affinity and efficacy between the two endocannabinoids at both cannabinoid receptors. Because 
FAAH is the primary compound responsible for degradation of AEA, inhibition of FAAH 
increases levels of AEA (as well as other fatty acid amides). Drugs that inhibit FAAH, and thus 
slow the degradation of AEA, often exert similar effects as CB1 agonists as a result of increased 
AEA activity (Moreira et al., 2015). MAGL inhibitors can also produce effects similar to CB1 
agonists by increasing 2-AG levels, and thus increasing CB1 activity (Reggio, 2009). Enzyme 
inhibitors are an indirect method of increasing CB1 activity because they operate strictly by 
altering levels of endogenous cannabinoids, and may produce fewer side effects than direct 
agonists (e.g., Alvarez-Jaimes & Palmer, 2011; Piomelli et al., 2006). Thus, the present study 
will focus on effects of increased AEA and 2-AG levels through drugs that inhibit FAAH or a 
combination of FAAH and MAGL. 
Delay Discounting and Cannabinoids 
Delta-9 tetrahydrocannabinol (THC) and synthetic cannabinoid agonists are widely 
consumed worldwide and are legal in many states (“Marijuana,” 2017). Given the proliferation 
of cannabinoid use, the endocannabinoid system’s involvement in both DA and 5-HT systems 
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(Lòpez-Moreno et al., 2008), and the high concentration of CB1 receptors in the NAc and PFC 
(Dove Pettit, Harrison, Olson, Spencer, & Cabral, 1998; Herkenham et al., 1990), investigation 
into the safety and efficacy of drugs that affect this system is warranted. There is limited research 
with inconsistent findings on the relation between the endocannabinoid system and delay 
discounting (e.g., Tanno, Maguire, Henson, & France, 2014; Wiskerke, Stoop, Schetters, 
Schoffelmeer, & Pattij, 2011), and although enzyme inhibitors may be the least addictive and 
least harmful of cannabinoid drugs (e.g., Alvarez-Jaimes & Palmer, 2011; Piomelli et al., 2006), 
they have received minimal attention in operant research. The lack of consistent evidence 
regarding delay discounting and the endocannabinoid system may be due in part to several 
reasons, including methodological differences across experiments, the variety of natural and 
synthetic agonists that act on cannabinoid receptor sites, and/or the inherent complexity of a 
neurotransmitter system that modulates other neurotransmitter systems.  
 Delta-9 tetrahydrocannabinol. THC, naturally found in Cannabis sativa, is a partial 
agonist for both CB1 and CB2 (Govaerts, Hermans, & Lambert, 2004). Effects of THC on delay 
discounting have been studied in both humans and non-human animals, with conflicting results 
and varying degrees of methodological consistency (e.g., McDonald, Schleifer, Richards, & de 
Wit, 2003; Metrik et al., 2013). In human research, the delay-discounting data have come 
primarily from hypothetical questions such as “Would you rather have $10.00 in 30 days or 
$2.00 at the end of the session?” administered after participants either inhaled marijuana smoke 
or ingested capsules containing varying amounts of THC (McDonald et al., 2003; Metrik et al., 
2013). Neither McDonald et al. (2003) nor Metrik et al. (2013) found significant differences 
between drug and placebo groups in delay discounting. However, due in part to the difficulty in 
obtaining accurate doses via smoke inhalation, the potential validity issues inherent in self-
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reported dependent measures (e.g., Lloyd, 1992), and the differences between pure THC and the 
mixture of 80 or more cannabinoids found in marijuana (El-Alfy et al., 2010), further 
investigation into THC’s effects on delay discounting in humans is needed. 
In non-human animal research, procedures and results have varied considerably as well. 
In a recent study, Tanno, et al., (2014) exposed experimentally naïve Sprague-Dawley rats to a 
delay-discounting procedure in which rats were given a choice between two levers: one 
associated with three pellets after a signaled delay (0, 4, 8, 16, or 32 s), and one associated with a 
single pellet delivered immediately. After an initial experiment in which rats were exposed to 
amphetamine, methylphenidate, and morphine and tested on a delay-discounting procedure, 
doses of 0.32, 3.2, and 5.6 mg/kg of THC were administered. A dose-dependent increase in delay 
discounting (more impulsive choice) was observed after THC administration. Wiskerke et al., 
(2011) trained Wistar rats to respond by nose-poking into one of two holes: one associated with 
four food pellets and an unsignaled delay (0, 5, 10, 20, or 40 s), and another associated with one 
food pellet presented immediately. After exposure and testing with combinations of 
amphetamine, and several synthetic cannabinoid agonists, rats were given doses of THC alone at 
0.5, 1.0, and 2.0 mg/kg. A dose-dependent decrease in delay discounting (less impulsive choice) 
was observed, and a statistically significant decrease from vehicle was found at the 2.0 mg/kg 
dose. These opposing findings, although likely in part a reflection of methodological differences, 
suggest a complex role for the endocannabinoid system in delay discounting. 
Synthetic cannabinoids. The cannabinoid system can also be manipulated with synthetic 
cannabinoids, many of which are agonists that act directly on CB1 receptors. In a procedure 
similar to that of Wiskerke and colleagues, (2011), Pattij and colleagues (2007) found no 
changes in delay discounting for Wistar rats following acute administration of the potent CB1 
DELAY DISCOUNTING AND CANNABINOID ENZYME INHIBITORS   
 
9
synthetic agonist WIN55,212-2 in doses up to 3.0 mg/kg. Adriani, Caprioli, Granstrem, Carli, 
and Levola (2003) used a procedure with signaled delays (0, 10, 20, 30, 45, 60, 80, 100 s) and 
five food pellets delivered for nose-pokes associated with the larger reinforcer. Under this 
procedure, they observed decreases in delay discounting (less impulsive choice) after acute 
administration of WIN55,212-2 (2.0 mg/kg) in Spontaneously Hypertensive Rats with reduced 
CB1 receptor density, but not in Wistar-Kyoto rats with normal CB1 receptor density. Similar to 
non-human animal research with THC, this limited and inconsistent experimental evidence with 
synthetic agonists suggests that further research is needed to understand the complex role that the 
endocannabinoid system plays in delay discounting. 
Enzyme inhibitors. Few studies have been conducted that directly examine the effects of 
cannabinoid enzyme inhibitors on delay discounting, but what evidence there is suggests a 
relation may exist. Marco et al. (2007) found that a low dose of the potent FAAH inhibitor 
URB597 resulted in decreases in delay discounting for Wistar rats that had experienced early 
maternal deprivation, but not for control rats. Just as in the above-mentioned studies, results from 
Marco et al., (2007) suggest a complex relation between the endocannabinoid system and delay 
discounting. 
FAAH inhibitors, like URB597, also have therapeutic promise in a number of areas 
outside of delay discounting. In non-human animals, URB597 can reverse cannabinoid- and 
morphine-induced cognitive deficits, prevent tolerance to morphine, promote social behavior, 
reduce nausea and inflammation, prevent and reverse symptoms of depression and anxiety, and 
promote analgesia, all with minimal abuse potential (Bortolato et al., 2007; Cross-Mellor, 
Ossenkopp, Piomelli, & Parker, 2007; Hasanein & Ghafar-Vahed, 2016; Hasanein & Teimuri 
Far, 2015; Jayamanne et al., 2006; Justinova et al., 2008; Kwilasz, Abdullah, Poklis, Lichtman, 
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& Negas, 2014; Manduca et al., 2014; Stunkard, 2009). Given its potential for therapeutic use in 
these other areas and its aforementioned minimal health risks and low potential for abuse, 
URB597 should be studied further for its potential behavioral effects on impulsive choice in a 
delay-discounting procedure. 
  Although FAAH inhibitors have been studied for their effects on delay discounting to 
some extent, no studies to date have been published on the role of MAGL inhibitors in delay 
discounting. Selective MAGL inhibitors are mostly studied for their physiological effects, but the 
dual FAAH/MAGL inhibitor JZL195 exerts strong motoric effects in rats (Seillier, Dominguez 
Aguilar, & Giuffrida, 2014). Effects of dual FAAH/MAGL inhibitors such as JZL195 often 
resemble those of THC on physiological and behavioral responses such as reduced 
inflammation-induced allodynia, hypolocomotion, and reductions in intracranial self-stimulation 
and heroin self-administration. Therefore, dual inhibitors could have effects similar to THC on 
delay discounting (Adamson, Mitchell, Kazantzis, & Vaughan, 2016; Guindon, 2016; Negus & 
Miller, 2014; Pacher, Bàtkai, & Kunos, 2006; Seillier et al., 2014; Wilkerson et al., 2016).  
Statement of the Problem 
Prior research indicates an important but complex role for the endocannabinoid system in 
delay discounting, as evidenced by changes in measures of delay discounting following 
administration of cannabinoid drugs, changes in 5-HT and DA levels after administration of such 
drugs (e.g., Lòpez-Moreno et al., 2008; Marco et al., 2007), and high cannabinoid receptor 
densities in brain regions involved in delay discounting (Herkenham et al., 1990). The purpose of 
the present experiment is to assess and compare effects of a FAAH inhibitor and a dual 
FAAH/MAGL inhibitor on delay discounting in rats. As a FAAH inhibitor, URB597 slows the 
breakdown of AEA and thus increases the duration of its activity. As a dual FAAH/MAGL 
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inhibitor, JZL195 slows the breakdown of 2-AG and AEA and thus increases their durations of 
activity. Given that URB597 and JZL195 exert many of the same behavioral effects as direct 
cannabinoid agonists, and that both of these drugs alter levels of endocannabinoids that induce 
changes in 5-HT and DA in brain regions related to delay discounting, it is likely that they will 
also have an effect on delay discounting.  
Method 
Subjects 
 Eight experimentally naïve male Sprague-Dawley rats served as subjects. All rats were 
pair-housed in controlled environmental conditions (temperature, 24°C; 12-h reverse light/dark 
cycle), with continuous access to water in home cages. Sessions were conducted at 
approximately the same time each day, five to six days per week (Monday-Saturday). Rats were 
fed approximately 16 g of food per cage approximately 30 min following sessions, resulting in 
approximately 22 h of food restriction. All procedures were approved by the Institutional Animal 
Care and Use Committee at West Virginia University. 
Apparatus 
Sessions were conducted in eight standard operant-conditioning chambers for rats, each 
enclosed in a melamine sound-attenuating cubicle (Med Associates, VT). Each chamber 
contained a working area of 30.5 cm by 24.5 cm by 21.0 cm, a grid floor, and a 45-mg pellet 
dispenser with a pellet receptacle centered between two retractable response levers. Levers were 
11.5 cm apart from each other and required at least 0.25 N of force for a response to be recorded.  
Levers were 4.8 cm wide, protruded 1.9 cm into the chamber, and were elevated 8 cm from the 
grid floor. Two 28-V stimulus lights, 2.5 cm in diameter, were approximately 7 cm above each 
lever. Each chamber had a 28-V houselight on the wall opposite to the working wall, and a 
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ventilation fan to circulate air and to mask extraneous noise. Data collection and programmed 
consequences were controlled by a personal computer equipped with Med-PC software (Med 
Associates, VT). 
Drugs 
Vehicle was a 1:2:17 mixture of Tween 80, dimethyl sulfoxide (DMSO), and saline. This 
ratio was selected to include the smallest amount of DMSO necessary to dissolve the maximum 
amount of drug used in the study at an injection volume of 2 ml/kg (Cayman Chemical, 2017; 
Sigma-Aldrich, 2017). URB597 (3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl)-cyclohexylcarbamate 
and JZL195 4-nitrophenyl 4-(3-phenoxybenzyl)piperazine-1-carboxylate were purchased from 
Cayman Chemical. The injection volume of 2 ml/kg was selected to maximize solubility while 
reducing potential irritation at the injection site caused by DMSO and because it had been safely 
used in numerous prior studies involving cannabinoid enzyme inhibitors. Prior studies informed 
the dose ranges selected for URB597 (Marco et al., 2007) and JZL195 (Seillier et al., 2014). All 
drugs were prepared from crystalline powder by adding the powder to pre-measured DMSO and 
crushing it with a metal spatula. The DMSO solution was then warmed to room temperature and 
sonicated for approximately five minutes. Once no more crystals were visible in the DMSO 
solution, Tween 80 was added, the solution was sonicated for another approximately 5 min, and 
saline was added to reach the final solution volume. Drug solutions were prepared no more than 
one week in advance and stored in a standard refrigerator. Raw crystalline powder was stored in 
a freezer at -80 ℃. Drugs were injected 50 min prior to the beginning of test sessions, with an 
additional 10-min blackout at the beginning of each session for a total of 60 min of pretreatment 
time. This pretreatment time was selected for two reasons: JZL195 produces a pronounced effect 
on motor behavior in rats after 60 min, (Seillier et al., 2014) and although URB597 has a rapid 
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onset (approximately 15 min), the long duration of its effects on brain anandamide levels and 
rectal temperature (Piomelli et al., 2006) placed a 60-min pretreatment time well within the 
suitable range for capturing effects of both drugs and allowed for a constant pretreatment time 
across rats and conditions. URB597 and JZL195 were purchased from Cayman Chemical. 
Procedure  
Lever-press training.  At the beginning of each lever-press training session, both levers 
were extended into the chamber and food pellets were delivered on a conjoint variable-time (VT) 
60 s fixed-ratio (FR) 1 schedule of reinforcement. On this schedule, a food pellet was delivered 
an average of once every 60 s independent of responding, and also immediately following any 
lever-press response. Lever pressing did not affect delivery of pellets from the VT component of 
the schedule and each of these sessions terminated following 60 food-pellet deliveries. If lever 
pressing had not been acquired after five sessions, it was shaped by reinforcement of successive 
approximations. Lever-press shaping involved using a remote control to deliver food pellets 
while the experimenter observed the rat through the viewing hole in the operant-conditioning 
chamber. Initially, pellets were delivered for approaching closer and closer to the lever. Then, 
pellets were only delivered for touching the lever, first with either paw and then with both. 
Finally, pellets were only delivered for full lever presses, and this continued until a minimum of 
20 pellets were delivered for lever pressing. After lever-press acquisition, an FR 1 schedule of 
reinforcement alternating between levers was implemented. Alternating FR 1 sessions consisted 
of one lever extending into the chamber with a cue light illuminated over it. A response on this 
lever resulted in the delivery of a single food pellet. The FR 1 contingency and cue light 
alternated between the left and right levers after every five responses with each session lasting 
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until 40 pellets had been delivered. Alternating FR 1 sessions continued until lever pressing was 
consistent on both levers across sessions. 
Delay-discounting procedure. Following lever-press training, a delay-discounting 
procedure was implemented. Sessions began with a 10-min blackout. Each session consisted of 
40 trials separated into five blocks, with a new trial beginning every 100 s. As a result of this 
procedure, the inter-trial intervals (ITIs) varied in duration across each trial, depending on 
response latency and reinforcer delay. Each block began with two forced-exposure trials in 
which lever pressing produced the consequences for each choice available during that block. 
During each forced-exposure trial, the houselight was illuminated and a single randomly 
determined lever was extended into the chamber with its respective cue light illuminated. The 
lever retracted if a response was made, its respective cue light darkened, and either a single food 
pellet was delivered immediately or three food pellets were delivered after the programmed 
delay. Next, a second forced-exposure trial occurred in which the other lever was extended and 
its respective cue light was illuminated. A response on this lever was followed by similar 
consequences as in the initial forced-exposure trial (e.g., lever retracted, cue light darkened, and 
either the immediate or delayed food pellets were delivered). Following the forced-exposure 
trials, six free-choice trials occurred. Both levers were extended for free-choice trials and both 
cue lights were illuminated. Both consequences were available concurrently during free-choice 
trials, and a response on a lever resulted in either the smaller or the larger reinforcer being 
delivered, with the position of the lever for the larger reinforcer counterbalanced across rats. 
When a smaller reinforcer was delivered, the houselight flashed once as the food pellet was 
dispensed into the food trough. When a larger reinforcer was delivered, the houselight remained 
on for the duration of the delay, flashed three times as the three pellets were dispensed into the 
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food trough, and then remained off for the remainder of the trial. If a response was not made 
within 30 s of a trial onset, that trial would be recorded as an omission, the lever(s) would retract, 
the cue light(s) and houselight would darken, and a 70-s ITI would begin. If six or more 
omissions occured on free-choice trials, the data from that session were excluded from analyses.  
Baseline training. In order to establish discrimination of reinforcer amounts, baseline 
training began with consequences for pressing either lever delivered after a 0-s delay. Delays to 
the larger reinforcer were then increased across blocks. The delay to the smaller reinforcer was 
always 0 s. The series of delays to the larger reinforcer was 0, 10, 20, 40, and 60 s across blocks. 
The delay series was presented such that in the first block, the delay to the larger reinforcer and 
the smaller reinforcer was always 0 s. In the second block, the larger reinforcer was delivered 
after a delay of 10 s. In the third block, the larger reinforcer was delivered after a delay of 20 s. 
This procedure continued until all five delays had been presented, one in each block. Sessions 
terminated after 40 trials, of which, 10 were forced-choice trials and the remainder free choice 
trials.  
A minimum of 10 baseline sessions were conducted and baseline sessions continued until 
stability was observed. Stability criteria were defined as the absence of increasing or decreasing 
trends in the total number of larger-reinforcer choices during free-choice trials across the last five 
sessions, less than 20% variation from the grand mean in the total number of larger-reinforcer 
choices during each of the last five sessions, and a minimum of 80% larger-reinforcer choices in 
the 0-s delay block. When responding reached stability, a 0-s probe session was conducted 
during which all delay values were set to zero in order to test for discrimination of reinforcer 
magnitude (Cardinal et al., 2000; Diller, Saunders, & Anderson, 2008). Additional probe 
sessions were conducted as needed throughout the experiment if there was any evidence that 
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reinforcer magnitude was not controlling responding (e.g., near-exclusive responding on a single 
lever).  This only occurred for one rat, which was excluded due to near-exclusive responding on 
the lever associated with the larger reinforcer, even after the position of that lever was switched. 
Acute administration of URB597 or JZL195. Once baseline responding reached 
stability and initial probe sessions had been conducted, the same procedure used to establish 
baseline delay-discounting functions was used to test the effects of URB597 and JZL195. Drug 
or vehicle was administered to all rats on Tuesdays and Fridays so that there was always a 
minimum of two days between injections. Control sessions occurred on Mondays and Thursdays. 
Wednesday sessions were identical to control sessions, but were not included in the calculations 
for determining if drug should be administered. Drug administration only occurred if larger-
reinforcer choice was 80% or higher during the first free-choice block of the control session 
immediately prior to the test day. On any test day for which drug-administration criteria were not 
met, those sessions were identical to control sessions and drug testing did not resume until drug-
administration criteria were met. Vehicle was administered for at least two sessions prior to drug 
administration in order to allow for habituation to the injection procedure and to determine any 
vehicle-induced effects on behavior. Drug doses were administered in both ascending and 
descending sequences, with an additional administration of vehicle occurring between each 
sequence. Each dose of each drug was tested at least twice, except for 3.0 mg/kg URB597, with 
order of presentation counterbalanced such that four rats received URB597, and four received 
JZL195 first. The 3.0 mg/kg dose of URB597 was not repeated after observing no change in 
behavior following its initial administration.  
 
 




The primary dependent variable was the percentage of larger-reinforcer choice at each 
delay value. Delay-discounting functions were constructed for each rat as percent-larger-
reinforcer choice across each delay value in the terminal delay series. Secondary dependent 
variables included indifference points and AUC. A nonlinear regression was fitted to the choice 
data from the baseline condition and indifference points were calculated by interpolating the 
delay value at which choice for the larger reinforcer was 50% (e.g., Anderson & Woolverton, 
2005). AUC was calculated by drawing vertical lines from each data point to the normalized x-
axis and the combined area of the trapezoids drawn by these vertical lines was divided by the 
total area of the graph (Myerson et al., 2001). An analysis of variance (ANOVA) was conducted 
to assess the effects of each drug on percent-larger-reinforcer choice at each delay value. 
Additional ANOVAs were conducted to assess the effect of each drug on AUC and indifference 
points. Smaller percentages of larger-reinforcer choice, shorter indifference points, and lower 
AUC are all indicative of increased impulsive choice.  
Results 
Mean percentage of larger-reinforcer choice as a function of increasing delays for all rats is 
shown in Figure 1, with URB597 data in the top panel and JZL195 data in the bottom panel. A 
significant main effect of trial block was found for vehicle data, F(2.54, 50.83) = 63.46, which 
indicates that choice for the larger reinforcer occurred less often as delay values increased (delay 
discounting) when no drug was present. Note that one rat was excluded from the experiment due 
to consistent and exclusive choice for the larger reinforcer during baseline. 
A series of two-way repeated-measures ANOVAs were conducted to compare effects of 
each dose of URB597 (Figure 1, top panel) on percent-larger-reinforcer choice during each 
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block. There was no main effect of any dose of URB597. A statistically significant interaction 
between dose and block was observed at the 0.3 mg dose, F(3.05, 60.99) = 1.75, p < .01. A 
simple effects analysis showed that percent larger-reinforcer choice was higher during the 40-s 
block (p = .018).  
Figure 2 shows mean larger-reinforcer choice data for individual rats for vehicle and 
URB597. Although not statistically significant, URB597 generally increased choice for the 
larger reinforcer during the 20- and 40-s blocks for Rat 2, but decreased choice for the larger 
reinforcer during some blocks for Rats 5, 7, and 8. Responding was almost completely 
unchanged relative to vehicle by URB597 for Rats 3, 4, and 6.  
A series of two-way repeated-measures ANOVAs were conducted to compare effects of 
each dose of JZL195 (Figure 1, bottom panel) on percent larger-reinforcer choice during each 
block. There was no main effect of any dose of JZL195. A statistically significant interaction 
between dose and block was observed at the 7.5 mg dose, F(2.64, 44.88) = 6.52, p < .01. A 
simple main effects analysis showed that percent larger-reinforcer choice was higher during the 
0-s block (p = .002) and lower during the 60-s block (p = .014).  
Figure 3 shows mean larger-reinforcer choice data for individual rats for vehicle and 
JZL195. Disruptions to responding were apparent but unsystematic. At higher delay values, 
larger-reinforcer choice tended to increase relative to vehicle for Rat 4 with the 7.5 mg/kg dose, 
but was decreased during the first two blocks. A similar pattern was present in the responding of 
Rat 5 at the 7.5 mg/kg dose. Larger-reinforcer choice for Rat 7 was disrupted at all delay values 
at the 5.0 and 7.5 mg/kg doses, although not in a systematic direction. Larger-reinforcer choice 
for Rat 8 decreased at lower delay values and increased at higher delay values with doses of 5.0 
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mg/kg JZL195, but was slightly reduced at all delay values for the 7.5 mg/kg dose. Responding 
was almost completely unchanged relative to vehicle by JZL195 for Rats 2, 3, and 6.  
A one-way repeated-measures ANOVA was conducted to compare effects of each dose of 
JZL195 and URB597 on AUC, indifference points, omissions, and latency. No statistically 
significant effect of any dose of either drug was observed (data not shown). Similarly, 
differences in number of response omissions were not statistically significant between vehicle 
and drug days. Response latency increased following administration of 7.5 mg/kg of JZL195 (M 
= 171.29, SE = 11.20) relative to vehicle (M = 95.12, SE = 5.27).  
Furthermore, additional visual analyses were conducted by selecting injection days when 
individual responding appeared to be altered and comparing those data with data from the days 
immediately preceding and following injection, as well as with the most recent vehicle injection 
rather than the average of all vehicle days. No differences in percent larger-reinforcer choice 
were evident that were not already visible in Figures 2 and 3.  
 Discussion 
Neither URB597 nor JZL195 had a systematic effect on any measure of impulsivity (i.e., 
AUC, indifference points, percent larger-reinforcer choice), at any dose. There are several 
possible interpretations of these data. One is that the task used was not sensitive enough to 
capture effects of URB597 and only captured effects of JZL195 at the most extreme delay 
values. Another possibility is that some part of the procedure prevented the drugs from being 
biologically available, possibly due to an error either in their preparation or administration. A 
third possibility is that the conditions required for an effect of one or both drugs on delay 
discounting to be observed were not met in the present experiment. Finally, it is also possible 
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that cannabinoid enzyme inhibitors or the endocannabinoid system in general are not involved in 
delay discounting. Each of these possibilities will be discussed in greater detail.  
Responding was disrupted for some rats to some extent at several doses of both drugs. 
While not statistically significant, these disruptions may represent a behaviorally significant 
effect that the present procedure was not sensitive enough to fully detect. Impulsivity may have 
been affected in ways that could have been seen with a different delay-discounting task, different 
parameters in the present task, or a different measure of impulsivity altogether. For instance, 
while strain differences have been observed between Lewis and Fischer 344 rats in delay-
discounting and other impulsivity-related tasks (e.g., Anderson & Woolverton, 2005; Hamilton, 
Potenza, & Grunberg, 2014), strain differences do not seem to affect probability discounting 
(Ozga-Hess, Vonder Haar, & Anderson, unpublished).  
Probability discounting is another form of impulsive choice (sometimes deemed “risky 
choice”), in which the larger reinforcer is delivered probabilistically rather than after a delay. In 
probability discounting, the impulsive choice would be selecting the larger reinforcer when the 
product of the probability of the larger reinforcer being delivered and the magnitude of the larger 
reinforcer are larger than the product of the same parameters of the smaller reinforce (e.g., 
choosing 3 pellets at 25% probability of delivery is more impulsive than choosing 1 pellet with 
100% probability of delivery). While delay- and probability-discounting procedures are both 
thought to measure “impulsivity” in a choice paradigm, it has become increasingly clear in 
recent years that they are not identical processes. For example, smaller reinforcers are discounted 
more steeply in delay discounting, while the opposite is true in probability discounting (Estle, 
Green, Myerson, & Holt, 2006). Furthermore, strain differences are seen between Fischer 344 
and Lewis rats in delay discounting, but not probability discounting (Ozga-Hess, Vonder Haar, & 
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Anderson, unpublished). Probability discounting likely reflects a similar, although separate 
process from delay discounting. Therefore, it is possible that drug effects not observed in a 
delay-discounting paradigm could be seen in a probability-discounting procedure. Future 
research could examine this possibility by testing effects of URB597 and JZL195 in a 
probability-discounting paradigm.  
Although there is no published research on enzyme inhibitors and probability discounting 
to date, many different cannabinoid drugs have been studied for their effects on various other 
impulsivity-related behaviors and tasks. The type of cannabinoid and the way impulsivity is 
being measured appear to be important determinants in whether a cannabinoid drug will affect 
responding. Ferland et al. (2018) found that THC and synthetic CB1 agonist WIN55,212-2 
exerted modest effects on motor impulsivity, but not choice impulsivity in the rodent gambling 
task. In the same study, URB597 was found to exert no effect on any measure of impulsivity. 
Conversely, Khani et al. (2015) found that increased cannabinoid signaling in the OFC increased 
delay discounting but not discounting based on effort, while the inverse was true for the anterior 
cingulate cortex. Nonetheless, delay-discounting procedures identical to those used in the present 
study have been effective at detecting effects of numerous drugs including diazepam, nicotine, 
amphetamine, methylphenidate, and caffeine (Anderson & Diller, 2010; Diller, et al., 2008; 
Huskinson & Anderson, 2012; Krebs, et al., 2016; Slezak, & Anderson, 2011).  
The lack of statistically significant results suggests that it is possible that cannabinoid 
drugs produce no effect on delay discounting. However, given the disruptions to responding 
mentioned above and the mixed effects seen in prior research, it is more likely that they produce 
a less-than-robust effect that the present experiment was unable to detect for at least two possible 
reasons. One possibility is that individual differences in responding were washed out by the 
DELAY DISCOUNTING AND CANNABINOID ENZYME INHIBITORS   
 
22
averaging of data across rats. Another possibility is that if responding shifted across time, the 
averaging of a relatively small number of data points across a relatively large time span (e.g., 
two administrations of a particular dose separated by a number of weeks) could have obscured a 
drug effect. To address the first possibility, percent larger-reinforcer choice for individual rats 
was visually inspected after being plotted as a function of delay for each dose of each drug (see 
Figures 2 and 3). Responding appeared to be disrupted at some delay values for some rats and 
some doses (e.g., Rat 7 in Figures 2 and 3). Still, drug and vehicle data were collected over a 
period of approximately three months, which left open the possibility that gradual shifts in 
responding and averaging of multiple data points could have obscured a drug effect. Visual 
analysis did not provide any more information about changes in responding at a more molecular 
level. Unfortunately, the ability of most statistical methods to detect an effect is based on the 
number of subjects or observations, and the ANOVA family of analyses is likely the most well-
suited method for analyzing data as they were collected in the present experiment. Future 
research should be designed with the ability to detect small effect sizes in mind (e.g., larger 
sample size, more drug administrations).  
A clear inhibitory effect of JZL195 on motor behavior in rats has been demonstrated in 
past studies, but responding in the present study was largely unaffected (e.g., Long et al., 2009; 
Seillier et al., 2014). While motor behavior was not directly recorded in the present study, 
omissions were were not affected by administration of any dose of JZL195 and latency to 
respond was only affected at the 7.5 mg/kg dose. This leaves open the possibility that an error in 
the process of drug preparation or administration occurred and the drugs were not bioavailable or 
active in-vivo. Still, the statistically significant disruption of responding observed following drug 
administration on some days for some rats at some delay values suggests that the drugs were 
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bioavailable but did not produce a robust behavioral effect (see individual graphs of percent 
larger-reinforcer choice for Rats 4, 5, 7, and 8 in Figure 3). 
To rule out the possibility that the drugs were not bioavailable, a behavioral task in which 
JZL195 and URB597 are known to produce effects could be used to ensure that the drugs were 
behaviorally active, regardless of their effects on delay-discounting. Although there is a paucity 
of behavior-analytic research on cannabinoid drugs, there is a standard “tetrad” of physiological 
effects that are produced by CB1 agonists and some enzyme inhibitors (e.g., Fride, Perchuk, 
Hall, Uhl, & Onaivi, 2006; Long et al., 2009). These effects include analgesia, catalepsy, 
hypomotility, and hypothermia. Specifically, JZL195 has been shown to produce all of these 
effects in mice and at least hypomitility in rats (Bedse et al., 2018; Limebeer et al., 2013; Long et 
al., 2009; Seiller et al., 2014). URB597 has been shown to produce analgesia, but not catalepsy, 
hypomotility, or hypothermia in rats and mice (Piomelli et al., 2006).  
Administering part or all of the tetrad tests would be a way to ensure that the drug 
vehicle, pretreatment time, and route of administration were not the reason for any lack of effect 
on behalf of the drugs. In the present study, vehicle preparation, pretreatment time, and route of 
administration were accounted for and informed by prior experiments (Marco et al., 2007; 
Piomelli et al., 2006; Seillier et al., 2014), but replication of a reliable drug effect (any of the four 
tetrad effects for JZL195, analgesia for URB597) under conditions identical to those used in the 
present study would provide more certainty that these drugs are biologically active but do not 
affect impulsive choice. 
Marco et al., (2007) found that URB597 significantly reduced delay discounting in rats, 
but only in rats that had elevated baseline levels of impulsivity following maternal separation 
early in life. Similarly, while there is little evidence for effects of cannabinoids on impulsivity in 
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humans in general (McDonald et al., 2003; Metrik et al., 2013), a modest improvement in motor 
impulsivity was observed in ADHD patients following treatment with a THC/CBD mixture 
(Cooper et al., 2017). These baseline- or impairment-dependent effects are also seen in studies 
where URB597 alleviates or prevents cognitive deficits, (e.g., responding in a passive avoidance 
test, Hasanein & Ghafari-Vahed, 2016), but has no effect on unimpaired animals. 
Another factor that may affect when enzyme inhibitors such as JZL195 and URB597 
alter behavior is the amount of endogenous cannabinoids present at the time of measurement. 
Because endogenous cannabinoids are synthesized on demand (Pertwee, 2004) and are only 
present when needed, inhibiting their metabolic enzymes should only produce an effect if there 
are already endogenous cannabinoids present whose metabolism could be inhibited or delayed. 
Evidence of this relation can be seen when exogenous AEA enhances anti-nausea effects of 
URB597 (Cross-Mellor, Ossenkopp, Piomelli, & Parker, 2007) or when URB597 enhances the 
hypothermic response produced by exogenous AEA in wild-type mice, but not in mice 
genetically altered to lack FAAH (Fegley et al., 2005). Inhibition of the metabolism of chemicals 
that are not present or are already exerting their maximal effect is one scenario in which enzyme 
inhibitors could produce no change in behavior. 
Another possibility is that neither the specific delay-discounting procedure, the method of 
administration, nor the conditions under which the experiment were conducted are to blame for 
the lack of effect. One could argue that the endocannabinoid system, which is the target of the 
drugs used in the present study, is simply not involved in delay discounting. This is unlikely for 
several reasons. First, the findings of prior research, although mixed, do demonstrate some 
relation between CB1 activity and delay discounting. Second, as mentioned above, the 
endocannabinoid system modulates the activity of other neurotransmitter systems known to 
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affect delay discounting. Third, given the proliferation of CB1 receptors in the central nervous 
system (particularly in areas already known to be involved in delay discounting), it is 
unreasonable to assume that those receptors do not also play a role in delay discounting.  
The relation between endogenous cannabinoid agonists, enzyme inhibitors, cannabinoid 
receptor activity, and behavioral outcomes is complex. A full understanding of the effects of 
enzyme inhibitors on behavior, to which the present study was designed to contribute, would 
benefit from first understanding how cannabinoids in general affect responding on simple 
schedules of reinforcement and punishment. From these baselines, environmental manipulations 
could be made (e.g., experimentally induced cognitive deficits, additional pharmacological 
manipulations, genetic alterations) and comparisons drawn. To examine the differences in 
behavioral effects between agonists and enzyme inhibitors, similar comparisons and 
manipulations could be made. While the present experiment was designed to contribute to the 
sparse literature on cannabinoid enzyme inhibitors and impulsivity, beginning with an 
understanding of how these drugs affect responding on simple schedules would likely be very 
useful in informing studies on more complex forms of responding, such as impulsivity.  
Future studies might also benefit from knowledge of cannabinoids and simple schedules 
by providing a baseline with which to determine if a drug is behaviorally active. In the present 
study, neither drug affected omissions or latencies consistently. Given that there is empirical 
evidence that JZL195 should have observable motoric effects at the doses used in the present 
study (Long et al., 2009; Seillier et al., 2014), a lack of systematic changes in omissions or 
latencies suggests that either the delay-discounting task was insensitive to the behavioral changes 
that occurred, or no behavioral changes occurred. If the task was not sensitive enough, 
knowledge of how cannabinoids affect responding on simple schedules could inform the 
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parameters of more complex procedures to increase their sensitivity. For example, if a drug 
effect was only apparent at higher values of a differential-reinforcement-of-low-rates (DRL) 
schedule of reinforcement, that information might inform the delay values used in a delay-
discounting procedure. If there was sufficient reason to believe the sensitivity of the task was not 
to blame and there was still no effect on responding, and the drugs were determined to be 
bioavailable, then that would imply that measures used in previous research do not correspond 
with the operant measures discussed here. 
 In summary, despite effects of cannabinoid drugs on many forms of behavior found in 
other experiments, no effect of URB597 or JZL195 on delay discounting was found in the 
present experiment. The reasons for a lack of statistically significant effects could be due to a 
number of limitations previously discussed. Before a conclusion can be drawn that enzyme 
inhibitors do not affect delay discounting, research should be conducted to determine if a 
different ask can reveal drug effects, to ensure that the drugs are bioavailable as prepared and 
administered in the present study, and to clarify what conditions are necessary for an effect to be 
observed (e.g., pre-existing deficits in responding, altered levels of endogenous cannabinoids, 
maternal deprivation).  
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Figure 1. Mean percentages of larger-reinforcer choice for all rats when vehicle, URB597 (top 
panel) or JZL195 (bottom panel) were administered. All doses are presented in mg/kg. Error bars 
indicate standard error of the mean (SEM). 




Figure 2. Mean percentages of larger-reinforcer choice for individual rats when vehicle or 
URB597 was administered. All doses are presented in mg/kg. Error bars indicate SEM. 
 





Figure 3. Mean percentages of larger-reinforcer choice for individual rats when vehicle or 
JZL195 was administered. All doses are presented in mg/kg. Error bars represent SEM. 




Glossary of Abbreviations and Acronyms 
• 5-HT – Serotonin, a neurotransmitter known to be involved in impulsivity. 
• DA – Dopamine, a neurotransmitter known to be involved in impulsivity. 
• PFC – Prefrontal Cortex, a brain region known to be involved in impulsivity. 
• NAc – Nucleus Accumbens Core, a brain region known to be involved in impulsivity. 
• AUC – Area Under the Curve, a common measure of impulsivity. 
• CB1 – Cannabinoid Receptor type 1, the cannabinoid receptor found predominantly in 
the brain and nervous system. 
• CB2 – Cannabinoid Receptor type 2, the cannabinoid receptor found predominantly on 
immune cells and tissue. 
• 2-AG – 2-arachidonoylglycerol, an endogenous cannabinoid 
• AEA – Anandamide, an endogenous cannabinoid 
• FAAH - Fatty Acid Amide Hydrolase, the enzyme responsible for the majority of AEA 
degradation. 
• MAGL – Monoacylglycerol Lipase, the enzyme responsible for the majority of 2-AG 
metabolism. 
 
